Inhibitory effects of sesamin on CYP2C9-dependent 7-hydroxylation of S-warfarin

被引:3
作者
Fujii, Miharu [1 ]
Yasuda, Kaori [1 ]
Sakaki, Toshiyuki [1 ]
机构
[1] Toyama Prefectural Univ, Fac Engn, Dept Pharmaceut Engn, 5180 Kurokawa, Imizu, Toyama 9390398, Japan
关键词
Sesamin; Warfarin; CYP2C9; Human liver microsomes; Competitive inhibition; ANTIOXIDATIVE METABOLITES; EPISESAMIN; LIVER; CYTOCHROME-P450; LIGNAN;
D O I
10.1016/j.dmpk.2020.05.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A recent report demonstrated that sesamin strongly and non-competitively inhibits S-warfarin 7-hydroxylation activity in human liver microsomes with a K-i value of 0.2 mu M. This finding suggests that sesamin predominantly binds to CYP2C9 at another site for which it has a higher affinity than its affinity for the active site, thereby inhibiting the activity of CYP2C9 non-competitively. In this study, we found that sesamin competitively inhibited the 7-hydroxylation activity of S-warfarin in human liver microsomes with a K-i value of 15.7 mu M. In addition, the recombinant CYP2C9-dependent 7-hydroxylation activity of S-warfarin was competitively inhibited by sesamin with a Ki value of 13.1 mu M. These results are consistent with the fact that sesamin is a good substrate of CYP2C9, and its activity follows Michaelis-Menten kinetics. As the plasma concentration of sesamin after its administration is usually lower than 0.01 mu M, the inhibition of S-warfarin metabolism by sesamin does not appear to be severe. (C) 2020 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:368 / 373
页数:6
相关论文
共 42 条
  • [21] Genetically based impairment in CYP2C8-and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: Is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?
    Agundez, Jose A. G.
    Garcia-Martin, Elena
    Martinez, Carmen
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (06) : 607 - 620
  • [22] 1-Aminobenzotriazole Coincubated with (S)-Warfarin Results in Potent Inactivation of CYP2C9
    Sodhi, Jasleen K.
    Ford, Kevin A.
    Mukadam, Sophie
    Wong, Susan
    Hop, Cornelis E. C. A.
    Khojasteh, S. Cyrus
    Halladay, Jason S.
    DRUG METABOLISM AND DISPOSITION, 2014, 42 (05) : 813 - 817
  • [23] Inhibitory Effects of Deoxypodophyllotoxin from Anthriscus sylvestris on Human CYP2C9 and CYP3A4
    Lee, Sang Kyu
    Kim, Yoon
    Jin, Changbae
    Lee, Seung Ho
    Kang, Mi Jeong
    Jeong, Tae Cheon
    Jeong, Seo Young
    Kim, Dong-Hyun
    Yoo, Hye Hyun
    PLANTA MEDICA, 2010, 76 (07) : 701 - 704
  • [24] In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose
    Tai, GY
    Farin, F
    Rieder, MJ
    Dreisbach, AW
    Veenstra, DL
    Verlinde, CLMJ
    Rettie, AE
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (07) : 475 - 481
  • [25] Clinical effect of CYP2C9*5/*6 genotype on a patient's warfarin dose requirement
    Quinn, Alison L. H.
    Liko, Ina
    Lee, James C.
    PHARMACOGENOMICS, 2017, 18 (11) : 1051 - 1057
  • [26] Inhibitory effects of cytochrome P450 enzymes CYP2C8, CYP2C9, CYP2C19 and CYP3A4 by Labisia pumila extracts
    Pan, Yan
    Tiong, Kai Hung
    Abd-Rashid, Badrul Amini
    Ismail, Zakiah
    Ismail, Rushli
    Mak, Joon Wah
    Ong, Chin Eng
    JOURNAL OF ETHNOPHARMACOLOGY, 2012, 143 (02) : 586 - 591
  • [27] Inhibitory effects of phthalimide derivatives on the activity of the hepatic cytochrome P450 monooxygenases CYP2C9 and CYP2C19
    Kolukisaoglu, Uener
    Wendler, Christian
    Goerdes, Dirk
    Diener, Annette
    Thurow, Kerstin
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2010, 25 (06) : 876 - 886
  • [28] Inhibitory effects of angiotensin receptor Blockers on CYP2C9 activity in human liver Microsomes
    Kamiyama, Emi
    Yoshigae, Yasushi
    Kasuya, Atsushi
    Takei, Makoto
    Kurihara, Atsushi
    Ikeda, Toshihiko
    DRUG METABOLISM AND PHARMACOKINETICS, 2007, 22 (04) : 267 - 275
  • [29] Effects of rare CYP2C9 alleles on stable warfarin doses in Chinese Han patients with atrial fibrillation
    Wang, Dongxu
    Dai, Da-Peng
    Wu, Hualan
    Chong, Jia
    Lu, You
    Yin, Ruoyun
    Zhao, Xinlong
    Zhao, Anxu
    Yang, Jiefu
    Chen, Hao
    PHARMACOGENOMICS, 2020, 21 (14) : 1021 - 1031
  • [30] Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction
    Fang, Zhong-Ze
    Zhang, Yan-Yan
    Ge, Guang-Bo
    Huo, Hong
    Liang, Si-Cheng
    Yang, Ling
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (02) : 193 - 199